长春高新(000661) - 2018 Q2 - 季度业绩预告

Financial Performance - The estimated net profit attributable to shareholders for the first half of 2018 is expected to be between 483 million yuan and 568 million yuan, representing a year-on-year growth of 70% to 100% compared to 284.04 million yuan in the same period last year[3]. - The basic earnings per share are projected to be approximately between 2.84 yuan and 3.34 yuan, compared to 1.67 yuan in the same period last year[3]. - The increase in net profit is primarily due to revenue growth from key pharmaceutical enterprises and an increase in revenue from real estate development projects[5]. Reporting and Auditing - The performance forecast has not been audited by registered accountants[4]. - The financial department's estimates will be detailed in the company's 2018 semi-annual report[6]. - The performance forecast period is from January 1, 2018, to June 30, 2018[3]. Investor Awareness - The company emphasizes the importance of investors being aware of investment risks[6]. - The announcement was made by the board of directors on July 7, 2018[7].